亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

濟南偉都化工醫藥有限公司  

主要致力于各種化工醫藥原料及中間體的生產研發及銷售,包括抗消炎鎮痛類,吡啶硼酸類,吡啶衍生物,苯硼酸,嘧啶類,碘吡啶類,以及吲哚類。

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:孟清
  • 電話:86-531-88681812
  • 郵件:wedochem01@126.com
  • 傳真:86-531-88873470
  • QQ:1666542939
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 47758-37-2
47758-37-2
單價 面議對比
詢價 暫無
發貨 山東濟南市付款后3天內
型號 47758-37-2
規格 9,9-二[(2,3-環氧丙氧基)苯基]芴 47758-37-2
過期 長期有效
更新 2013-11-20 11:47
 
詳細信息

9,9-二[(2,3-環氧丙氧基)苯基]芴  47758-37-2
英文名: 9,9-bis[4-(2-Glycidyloxyethyl)phenyl]fluorene
CAS 號: 47758-37-2
其他名: 2,2'-[9H-Fluoren-9-ylidene-bis(4,1-phenyleneoxymethylene)]bis-oxirane
分子量: 462.55
分子式: C31H26O4
規格:
外觀: 白色結晶粉末
熔點: 146-148℃
含量: ≥98.0%
用途: 用于功能環氧樹脂的合成
包裝: 紙板桶25kg/桶,內襯聚乙烯塑料袋 。
孟清 0531-55500012 13678820114
©2025 濟南偉都化工醫藥有限公司 版權所有   技術支持:化工網   訪問量:38616  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |